0001213900-25-004622.txt : 20250117 0001213900-25-004622.hdr.sgml : 20250117 20250117161511 ACCESSION NUMBER: 0001213900-25-004622 CONFORMED SUBMISSION TYPE: SCHEDULE 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250117 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Scilex Holding Co CENTRAL INDEX KEY: 0001820190 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-91963 FILM NUMBER: 25538832 BUSINESS ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: (650) 516-4310 MAIL ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 FORMER COMPANY: FORMER CONFORMED NAME: Scilex Holding Company/DE DATE OF NAME CHANGE: 20221117 FORMER COMPANY: FORMER CONFORMED NAME: Vickers Vantage Corp. I DATE OF NAME CHANGE: 20200804 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ORAMED PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0001176309 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980376008 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G BUSINESS ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 646-844-1164 MAIL ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Integrated Security Technologies, Inc. DATE OF NAME CHANGE: 20040614 FORMER COMPANY: FORMER CONFORMED NAME: IGUANA VENTURES LTD DATE OF NAME CHANGE: 20020625 SCHEDULE 13G 1 primary_doc.xml SCHEDULE 13G 0001176309 XXXXXXXX LIVE Common Stock par value $0.0001 per share 01/13/2025 0001820190 Scilex Holding Company 80880W106 960 San Antonio Road, Palo Alto, CA 94303 Rule 13d-1(c) Oramed Pharmaceuticals Inc. DE 15500000.00 0.00 15500000.00 0.00 15500000.00 N 6.2 CO Note to Rows 5, 7, 9: Comprised of (i) 9,000,000 shares of common stock, par value $0.0001 per share ("Common Stock"), of Scilex Holding Company (the "Issuer"), and (ii) 6,500,000 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of the date on which this Schedule 13G has been filed with the Securities and Exchange Commission ("SEC"). Note to Row 11: Percent of class beneficially owned is calculated based on 243,312,885 shares of Common Stock outstanding as of January 6, 2025 as represented by the Issuer, plus 6,500,000 shares of Common Stock issuable upon exercise of warrants held by the Reporting Person that are exercisable within 60 days of the date on which this Schedule 13G has been filed with the SEC. Scilex Holding Company 960 San Antonio Road, Palo Alto, California, 94303 Oramed Pharmaceuticals Inc. ("Oramed") 1185 Avenue of the Americas, Third Floor, New York, NY 10036 Delaware Y The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The amount beneficially owned is comprised of (i) 9,000,000 shares of common stock, par value $0.0001 per share ("Common Stock"), of Scilex Holding Company (the "Issuer"), and (ii) 6,500,000 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of the date on which this Schedule 13G has been filed with the Securities and Exchange Commission ("SEC"). The information required by Item 4(b) is set forth in Row 11 of the cover page for the Reporting Person and is incorporated herein by reference. The percent of class beneficially owned reported in Row 9 of the cover page for the Reporting Person is calculated based on 243,312,885 shares of Common Stock outstanding as of January 6, 2025 as represented by the Issuer, plus 6,500,000 shares of Common Stock issuable upon exercise of warrants held by the Reporting Person that are exercisable within 60 days of the date on which this Schedule 13G has been filed with the SEC. This calculation results in 6.2 15,500,000 0 15,500,000 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Oramed Pharmaceuticals Inc. /s/ Avraham Gabay 01/17/2025